Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes Mellitus: Introduction

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chlorinated Naphthalene Poisoning.

British medical journal·2010

Same author

Diagnosis of Carcinoma.

Canadian Medical Association journal·2010

Same author

Autopsy Lung Cultures.

Canadian Medical Association journal·2010

Same author

The Definition of a Specialist.

Canadian Medical Association journal·2010

Same author

Alloxan diabetes: the sorcerer and his apprentice.

Diabetologia·1982

Same author

Venereal disease vs Bowen's disease.

JAMA·1977

Same journal

Dr Archibald Hewan (1832-1883) and the University of Glasgow's medical libraries.

The journal of the Royal College of Physicians of Edinburgh·2025

Same journal

Joyce Grainger Learning Centre.

The journal of the Royal College of Physicians of Edinburgh·2025

Same journal

Features in this issue.

The journal of the Royal College of Physicians of Edinburgh·2025

Same journal

An unusual case of cutaneous tuberculosis and paradoxical TB in a patient with spondyloarthritis treated with adalimumab.

The journal of the Royal College of Physicians of Edinburgh·2025

Same journal

Leptospiral infection overlapping with autoimmune hepatitis: A diagnostic conundrum.

The journal of the Royal College of Physicians of Edinburgh·2025

Same journal

Tocilizumab vs bevacizumab in critically ill COVID-19 patients: Registry-based prospective study.

The journal of the Royal College of Physicians of Edinburgh·2025

See all related articles

Search research articles

Related Experiment Video

Updated: May 26, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Alloxan diabetes: a discovery, albeit a minor one.

The Journal of the Royal College of Physicians of Edinburgh

|November 19, 2002

Summary

This summary is machine-generated.

Alloxan, a compound rooted in early organic chemistry, was discovered to induce diabetes mellitus in animals via a single injection. This 1942 finding by Dunn and McLetchie utilized a substance with a rich chemical history.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Related Experiment Videos

Last Updated: May 26, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Area of Science:

Organic Chemistry
Endocrinology
Toxicology

Background:

Alloxan, a derivative of uric acid, has origins in early systematic organic chemistry, discovered by Wöhler and Liebig.
The compound's name derives from allantoin and oxaluric acid ('oxalsaüre'), highlighting its historical chemical connections.

Discussion:

The 1942 discovery by John Shaw Dunn and Norman McLetchie in Glasgow demonstrated alloxan's potent diabetogenic properties in laboratory animals.
This finding established alloxan as a critical tool in diabetes research, enabling the study of the disease's mechanisms.

Key Insights:

A single injection of alloxan reliably induces diabetes mellitus in experimental models.
Alloxan selectively destroys pancreatic beta cells, providing a specific model for studying type 1 diabetes.

Outlook:

Further research into alloxan's mechanism of action can reveal new therapeutic targets for diabetes.
The historical context of alloxan underscores the long-standing relationship between fundamental organic chemistry and biomedical discovery.